Giving an individual special access to an experimental obesity drug is highly unusual.

The “triple-G” weight loss drug, Pfizer’s lung cancer trial results, and more biotech news from The Readout

Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of the top 10 drugs in 2032.

Tuesday, June 23 – Wegovy, Zepbound named first choice for obesity treatment in new guidelines

Tuesday, June 23 – Researchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty Images

A meta-analysis found that one type of GLP-1 medication may be more effective than others. 

The analysis showed that GLP-1s containing tirzepatide (Zepbound, Mounjaro) helped people lose more weight than those containing semaglutide (Ozempic, Wegovy). 

Liraglutide (Saxenda) had the lowest weight loss percentage among users. 

The success of tirzepatide may be due to its dual mechanism, which targets multiple receptors.

Tuesday, June 23 – (MedPage Today) — At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with a weekly dose of the ultra-long-acting investigational GLP-1 agonist berobenatide…

Tuesday, June 23 – For many people, the thought of a tasty burger or a cold pint of beer conjures a vivid mental image and drives behavior. This link between thinking and doing serves a clear function—it motivates us to get the necessities of life.

Monday. June 22 – The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. Experts now envision a future where medications, minimally invasive procedures, surgery, and precision medicine work together to deliver better long-term results.

Saturday, June 20 – GLP-1s may help reduce impulsivity, alcohol intake, and violent behaviors in adults. Image Credit: munro/gettyimages

A recent study found that GLP-1 medications like Ozempic and Wegovy may help lower impulsive and violent behaviors.

The researchers noted that higher impulsivity and alcohol use were significantly associated with violent behavior overall, but were weaker among those using GLP-1s.

Saturday, June 20 – GLP-1 weight loss drugs like Ozempic are linked to cosmetic concerns, including sagging earlobes, deflated breasts and flatter buttocks, surgeons say.

FRIDAY, June 19, 2026 — Ozempic doesn’t only help people lose weight, but might also protect against broken bones, a new study says.
People with type 2 diabetes treated with semaglutide (Ozempic/Wegovy) had a 15% lower risk of bone…

Friday, June 19 – GLP-1 drugs show early promise for improving fertility in males and females

Friday, June 19 – Mayim Bialik recently shared the “nightmare” experience she had after using a GLP-1 drug. Image Credit: Laurent Koffel/Getty Images

Actor Mayim Bialik has shared her “nightmare” experience that left her with weeks of side effects after one GLP-1 medication dose. 

Bialik said her symptoms included severe diarrhea and full-body aches. 

She revealed that she tried a GLP-1 after her doctor suggested it may help with her autoimmune disease symptoms.

Friday, June 19 – Setting a weight loss goal may yield greater success with GLP-1 drugs like Zepbound. Image Credit: Crispin la valiente/GettyImages

A recent study found that people who set personal weight loss targets may achieve greater results with GLP-1 medications. 

People using tirzepatide (Zepbound or Mounjaro) saw more weight loss if they set goals or had previously tried structured diet plans.

Friday, June 19 – What’s next for GLP-1 weight loss drugs? Alex Hogan explores on the new episode of STATus Report. Watch now.

Friday, June 19 – (MedPage Today) — The FDA cleared Wave Neuroscience’s biomarker-guided neuromodulation system (MeRT) to treat post-traumatic stress disorder (PTSD), the company announced.
Gastrointestinal interoception was disrupted across multiple domains in…

WEDNESDAY, June 17, 2026 — Adults with obesity initiating glucagon-like peptide-1 receptor agonist (GLP-1RA) medications have a significant decrease in their physical activity, according to a study presented at ENDO 2026, the annual meeting of the…

WEDNESDAY, June 17, 2026 — More than half of adults with type 2 diabetes mellitus (T2DM) who discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reinitiate within one year, according to a study presented at ENDO 2026, the annual…

Wednesday, June 17 – Using GLP-1s may increase your risk of heat-related illnesses. Image Credit: Nora Carol Photography/Getty Images

GLP-1 medications may increase heat-related risks by suppressing thirst and reducing fluid intake.

Thirst reduction may lead to severe dehydration and even kidney damage. 

GLP-1 drugs may also lower blood pressure in some people, potentially leading to other heat-related issues in people with low blood pressure.

A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect how people act on impulses, though researchers stress that cause and effect have not been proven.

Wednesday, June 17 – New research finds GLP-1 users significantly reduced physical activity, with daily steps and exercise declining after starting a weight loss medication.

WEDNESDAY, June 17, 2026 — People with an autoimmune disease and obesity might lower their risk of dangerous blood clots and death by taking Ozempic or Zepbound, a new study says.
Autoimmune diseases like celiac disease, vitiligo, psoriasis…

Wednesday, June 17 – The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are not enough to address one of the nation’s most pressing chronic diseases.

Wednesday, June 17 – Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become popular for weight loss, but results vary from person to person and from drug to drug. Venky Soundararajan and colleagues explored the full range of responses to tirzepatide (e.g., Mounjaro or Zepbound) and semaglutide (e.g., Ozempic, Wegovy or Rybelsus) by analyzing de-identified electronic health records for matched cohorts of 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients. In the real world, outcomes ranged from minimal weight loss to more than a 25% reduction in body weight.

Wednesday, June 17 – Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties. 

Wednesday, June 17 – (MedPage Today) — A massive wave of new prescriptions for GLP-1 receptor agonists is expected following the July launch of a Medicare pilot program that offers the drugs for weight loss for a flat $50 monthly copay. (Axios)
Meanwhile, nearly…

TUESDAY, June 16, 2026 — Orforglipron is beneficial for blood glucose control in individuals with type 2 diabetes using metformin or taking insulin glargine, according to two studies published online June 8 in The Lancet and the Journal of the…

Monday, June 15 – Eli Lilly’s recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.

Monday, June 15 – Many people prescribed GLP-1 drugs for type 2 diabetes (such as Victoza, Ozempic, or tirzepatide) stop taking them, but a surprising number later return to treatment. Researchers found that newer medications appear to keep patients on therapy longer, while side effects remain a major reason for discontinuation.

Monday, June 15 – A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss. Researchers analyzing health records from nearly 60,000 adults found that people taking semaglutide experienced about 15% fewer fractures than those using other common weight-loss medications, despite losing more weight.

TUESDAY, June 16, 2026 — Folks losing weight on Ozempic or Zepbound tend to start slacking off when it comes to exercise, a new study says.
People’s daily step count and physical activity declined after starting a GLP-1 medication…

Tuesday, June 16 – One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

Tuesday, June 16 – Tirzepatide doesn’t just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

Tuesday, June 16 – (MedPage Today) — CHICAGO — The GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) was associated with a 15% lower risk for fractures in adults with type 2 diabetes, a review of medical records found.
In a matched analysis involving more…

MONDAY, June 15, 2026 — Selective targeting of myostatin by apitegromab preserves lean mass when combined with tirzepatide, according to a study published online June 8 in Nature Medicine.
Richard E. Pratley, M.D., from the AdventHealth…

MONDAY, June 15, 2026 — Among patients with preexisting hypertension taking antihypertensive medications, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with an increase in hypotensive-related events, according to a study…

Monday, June 15 – GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.

Monday, June 15 – GLP-1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago. In fact, the research team found GLP-1s may improve testosterone levels and sperm quality in men with obesity-related low testosterone, while also addressing the underlying effects of obesity.

Tuesday, June 16 – GLP-1s may aid bone health as well as weight loss in type 2 diabetes.

Monday, June 15 – Popular weight loss drugs, including Ozempic and Wegovy, have already transformed how people shop for food. Now, they’re impacting the way users buy their clothes as they slim down. But with so many shoppers uncertain about their fit and size, retailers are seeing a surge in returns that’s proving to be very costly. NBC’s Emilie Ikeda reports for TODAY.